332 related articles for article (PubMed ID: 1911826)
41. Biodistribution and immunotargetability of ganglioside-stabilized dioleoylphosphatidylethanolamine liposomes.
Litzinger DC; Huang L
Biochim Biophys Acta; 1992 Feb; 1104(1):179-87. PubMed ID: 1550846
[TBL] [Abstract][Full Text] [Related]
42. Influence of dose on liposome clearance: critical role of blood proteins.
Oja CD; Semple SC; Chonn A; Cullis PR
Biochim Biophys Acta; 1996 May; 1281(1):31-7. PubMed ID: 8652601
[TBL] [Abstract][Full Text] [Related]
43. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
44. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes.
Liu D; Mori A; Huang L
Biochim Biophys Acta; 1992 Feb; 1104(1):95-101. PubMed ID: 1550858
[TBL] [Abstract][Full Text] [Related]
45. Sterically stabilized liposomes.
Woodle MC; Lasic DD
Biochim Biophys Acta; 1992 Aug; 1113(2):171-99. PubMed ID: 1510996
[TBL] [Abstract][Full Text] [Related]
46. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
48. Distribution within the organs of a reticuloendothelial system of liposomes containing lipid A.
Park YS; Huang L
J Drug Target; 1993; 1(4):325-30. PubMed ID: 8069575
[TBL] [Abstract][Full Text] [Related]
49. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
[TBL] [Abstract][Full Text] [Related]
50. Effect of ganglioside-GM1 on the order of phosphatidylcholine-cholesterol multilamellar liposomes. A fluorescence polarization study.
Hitzemann RJ
Chem Phys Lipids; 1987; 43(1):25-38. PubMed ID: 3581296
[TBL] [Abstract][Full Text] [Related]
51. Extended in vivo blood circulation time of fluorinated liposomes.
Santaella C; Frézard F; Vierling P; Riess JG
FEBS Lett; 1993 Dec; 336(3):481-4. PubMed ID: 8282115
[TBL] [Abstract][Full Text] [Related]
52. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.
Ho EA; Ramsay E; Ginj M; Anantha M; Bregman I; Sy J; Woo J; Osooly-Talesh M; Yapp DT; Bally MB
J Pharm Sci; 2010 Jun; 99(6):2839-53. PubMed ID: 20091826
[TBL] [Abstract][Full Text] [Related]
53. Monosialoganglioside GM1 shortens the blood circulation time of liposomes in rats.
Liu D; Liu F; Song YK
Pharm Res; 1995 Apr; 12(4):508-12. PubMed ID: 7596984
[TBL] [Abstract][Full Text] [Related]
54. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
[TBL] [Abstract][Full Text] [Related]
55. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes.
Lee JS; Ankone M; Pieters E; Schiffelers RM; Hennink WE; Feijen J
J Control Release; 2011 Oct; 155(2):282-8. PubMed ID: 21820023
[TBL] [Abstract][Full Text] [Related]
56. Liposome disposition in vivo. III. Dose and vesicle-size effects.
Abra RM; Hunt CA
Biochim Biophys Acta; 1981 Dec; 666(3):493-503. PubMed ID: 7034780
[TBL] [Abstract][Full Text] [Related]
57. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies.
Gabizon A; Price DC; Huberty J; Bresalier RS; Papahadjopoulos D
Cancer Res; 1990 Oct; 50(19):6371-8. PubMed ID: 1698120
[TBL] [Abstract][Full Text] [Related]
58. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
59. Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen.
Litzinger DC; Huang L
Biochim Biophys Acta; 1992 Aug; 1127(3):249-54. PubMed ID: 1511002
[TBL] [Abstract][Full Text] [Related]
60. Comparative effects of PEG-containing liposomal formulations on in vivo pharmacokinetics of streptokinase.
Jin SE; Kim IS; Kim CK
Arch Pharm Res; 2015 Oct; 38(10):1822-9. PubMed ID: 25851624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
